An observational study in Cardiogenic Shock, sponsored by Abiomed Inc.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 29th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:
Leipzig Heart Science gGmbH · Sites in Germany
Ages 18–80
University Hospital of Cologne · Sites in Germany
Ages 18–77
4TEEN4 Pharmaceuticals GmbH · Sites in Germany, Armenia, Belgium and 6 more countries
Ages 18–80
University Heart Center Freiburg - Bad Krozingen · Sites in Germany
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 60 across the 22 interventional studies, 138 across the 14 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Abiomed Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Abiomed Inc. is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
Johnson & Johnson has 7 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Cardiogenic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT07515508University Heart Center Freiburg - Bad KrozingenMultimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE | 2027-07-31 |
| NCT07687017Leipzig Heart Science gGmbHCRP Apheresis in Infarct-Related Cardiogenic Shock | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
The objective of this study is to develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module, which can replace invasive hemodynamic monitoring in the future.
Patients requiring cardiac Impella pump-support and intensive care therapy including cardiac output monitoring, eg. by pulmonary artery catheter at some point of therapy.
Initially, a collection of 250 patient days is aimed for. It is expected that each patient will be monitored by PAC for at least 48 hours, thus approximately 125 patients will be needed to achieve study objectives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence or planned placement of a cardiac output measurement
Exclusion Criteria:
Develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module.
Collection of hemodynamic parameters (Cardiac Output in l/min)
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
Collection of hemodynamic parameters (Blood Pressure in mmHg, Pulmonary Artery Pressure in mmHg, Central Venous Pressure in mmHg, Pulmonary Capillary Wedge Pressure in mmHg)
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
Collection of hemodynamic parameters (Mixed Venous Saturation in %)
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
Collection of hemodynamic parameters (Pulmonary Vascular Resistance in In dynes/sec/cm-5 )
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
Rate of Patient Survival
Time frame: Once the Impella support is permanently weaned, on average 2 days
Not enrolling at this site.
Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.
Of 85 observational studies under Shock, Cardiogenic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24. This study's planned 32 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.